MapLight Therapeutics Inc
Research MapLight Therapeutics Inc (MPLT) on Bullrun: market cap USD 569.78M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerMPLT
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 569.78M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 60.67M
- Free cash flow-USD 51.20M
Valuation Snapshot
latest market cap is USD 569.78M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | n/a | -USD 161.15M | -USD 138.61M | n/a | -18.56 | USD 46.73M | USD 5.80M | USD 458.37M |
| FY2024 | n/a | -USD 77.58M | -USD 79.59M | n/a | -105.38 | USD 38.25M | USD 6.58M | -USD 193.63M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 569.78M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 773.50M | n/a | n/a | n/a |
About MapLight Therapeutics Inc
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is MapLight Therapeutics Inc's market cap?
MapLight Therapeutics Inc's market capitalization is USD 569.78M.
What does MapLight Therapeutics Inc do?
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders.